Trends in Overall Survival among Patients Treated for Sarcoma at a Large Tertiary Cancer Center between 1986 and 2014
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. MCC Cancer Registry Data
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [Google Scholar] [CrossRef] [PubMed]
- Ferrari, A.; Dirksen, U.; Bielack, S. Sarcomas of Soft Tissue and Bone. Prog. Tumor. Res. 2016, 43, 128–141. [Google Scholar] [CrossRef] [PubMed]
- Ferrari, A.; Sultan, I.; Huang, T.T.; Rodriguez-Galindo, C.; Shehadeh, A.; Meazza, C.; Ness, K.K.; Casanova, M.; Spunt, S.L. Soft tissue sarcoma across the age spectrum: A population-based study from the Surveillance Epidemiology and End Results database. Pediatr. Blood Cancer 2011, 57, 943–949. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stojadinovic, A.; Leung, D.H.; Hoos, A.; Jaques, D.P.; Lewis, J.J.; Brennan, M.F. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann. Surg. 2002, 235, 424–434. [Google Scholar] [CrossRef]
- Hall, F.; Villalobos, V.; Wilky, B. Future directions in soft tissue sarcoma treatment. Curr. Probl. Cancer 2019, 43, 300–307. [Google Scholar] [CrossRef]
- Blay, J.Y.; Hindi, N.; Bollard, J.; Aguiar, S., Jr.; Angel, M.; Araya, B.; Badilla, R.; Bernabeu, D.; Campos, F.; Caro-Sanchez, C.H.S.; et al. SELNET clinical practice guidelines for soft tissue sarcoma and GIST. Cancer Treat. Rev. 2022, 102, 102312. [Google Scholar] [CrossRef] [PubMed]
- Jo, V.Y.; Fletcher, C.D. WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition. Pathology 2014, 46, 95–104. [Google Scholar] [CrossRef]
- ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2014, 25, iii113–iii123. [Google Scholar] [CrossRef]
- Gaspar, N.; Hawkins, D.S.; Dirksen, U.; Lewis, I.J.; Ferrari, S.; Le Deley, M.C.; Kovar, H.; Grimer, R.; Whelan, J.; Claude, L.; et al. Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. J. Clin. Oncol. 2015, 33, 3036–3046. [Google Scholar] [CrossRef] [Green Version]
- Gatta, G.; Botta, L.; Rossi, S.; Aareleid, T.; Bielska-Lasota, M.; Clavel, J.; Dimitrova, N.; Jakab, Z.; Kaatsch, P.; Lacour, B.; et al. Childhood cancer survival in Europe 1999–2007: Results of EUROCARE-5—A population-based study. Lancet Oncol. 2014, 15, 35–47. [Google Scholar] [CrossRef]
- Schabath, M.B.; Thompson, Z.J.; Gray, J.E. Temporal trends in demographics and overall survival of non-small-cell lung cancer patients at Moffitt Cancer Center from 1986 to 2008. Cancer Control 2014, 21, 51–56. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smith, A.W.; Seibel, N.L.; Lewis, D.R.; Albritton, K.H.; Blair, D.F.; Blanke, C.D.; Bleyer, W.A.; Freyer, D.R.; Geiger, A.M.; Hayes-Lattin, B.; et al. Next steps for adolescent and young adult oncology workshop: An update on progress and recommendations for the future. Cancer 2016, 122, 988–999. [Google Scholar] [CrossRef]
- Patel, S.R. Fifty years of advances in sarcoma treatment: Moving the needle from conventional chemotherapy to targeted therapy. Am. Soc. Clin. Oncol. Educ. Book 2014, 34, 259–262. [Google Scholar] [CrossRef]
- Jacobs, A.J.; Michels, R.; Stein, J.; Levin, A.S. Improvement in Overall Survival from Extremity Soft Tissue Sarcoma over Twenty Years. Sarcoma 2015, 2015, 279601. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, X.; Liang, X.; Wen, K. Clinical characteristics and prognosis of gastrointestinal stromal tumors with rare site metastasis (Review). Oncol. Lett. 2022, 24, 453. [Google Scholar] [CrossRef] [PubMed]
- Rammohan, A.; Sathyanesan, J.; Rajendran, K.; Pitchaimuthu, A.; Perumal, S.K.; Srinivasan, U.; Ramasamy, R.; Palaniappan, R.; Govindan, M. A gist of gastrointestinal stromal tumors: A review. World J. Gastrointest. Oncol. 2013, 5, 102–112. [Google Scholar] [CrossRef]
- Tap, W.D.; Wagner, A.J.; Schoffski, P.; Martin-Broto, J.; Krarup-Hansen, A.; Ganjoo, K.N.; Yen, C.C.; Abdul Razak, A.R.; Spira, A.; Kawai, A.; et al. Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA 2020, 323, 1266–1276. [Google Scholar] [CrossRef] [PubMed]
- Seddon, B.; Strauss, S.J.; Whelan, J.; Leahy, M.; Woll, P.J.; Cowie, F.; Rothermundt, C.; Wood, Z.; Benson, C.; Ali, N.; et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): A randomised controlled phase 3 trial. Lancet Oncol. 2017, 18, 1397–1410. [Google Scholar] [CrossRef] [Green Version]
- Judson, I.; Verweij, J.; Gelderblom, H.; Hartmann, J.T.; Schoffski, P.; Blay, J.Y.; Kerst, J.M.; Sufliarsky, J.; Whelan, J.; Hohenberger, P.; et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol. 2014, 15, 415–423. [Google Scholar] [CrossRef] [PubMed]
- Ryan, C.W.; Merimsky, O.; Agulnik, M.; Blay, J.Y.; Schuetze, S.M.; Van Tine, B.A.; Jones, R.L.; Elias, A.D.; Choy, E.; Alcindor, T.; et al. PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. J. Clin. Oncol. 2016, 34, 3898–3905. [Google Scholar] [CrossRef]
- Tap, W.D.; Papai, Z.; Van Tine, B.A.; Attia, S.; Ganjoo, K.N.; Jones, R.L.; Schuetze, S.; Reed, D.; Chawla, S.P.; Riedel, R.F.; et al. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): An international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2017, 18, 1089–1103. [Google Scholar] [CrossRef]
- Cutts, S.; Andrea, F.; Piana, R.; Haywood, R. The management of soft tissue sarcomas. Surgeon 2012, 10, 25–32. [Google Scholar] [CrossRef] [PubMed]
- HaDuong, J.H.; Martin, A.A.; Skapek, S.X.; Mascarenhas, L. Sarcomas. Pediatr. Clin. N. Am. 2015, 62, 179–200. [Google Scholar] [CrossRef]
- Gage, M.M.; Nagarajan, N.; Ruck, J.M.; Canner, J.K.; Khan, S.; Giuliano, K.; Gani, F.; Wolfgang, C.; Johnston, F.M.; Ahuja, N. Sarcomas in the United States: Recent trends and a call for improved staging. Oncotarget 2019, 10, 2462–2474. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nathan, H.; Raut, C.P.; Thornton, K.; Herman, J.M.; Ahuja, N.; Schulick, R.D.; Choti, M.A.; Pawlik, T.M. Predictors of survival after resection of retroperitoneal sarcoma: A population-based analysis and critical appraisal of the AJCC staging system. Ann. Surg. 2009, 250, 970–976. [Google Scholar] [CrossRef] [Green Version]
- Crompton, J.G.; Ogura, K.; Bernthal, N.M.; Kawai, A.; Eilber, F.C. Local Control of Soft Tissue and Bone Sarcomas. J. Clin. Oncol. 2018, 36, 111–117. [Google Scholar] [CrossRef] [Green Version]
- Miwa, S.; Yamamoto, N.; Hayashi, K.; Takeuchi, A.; Igarashi, K.; Tsuchiya, H. Therapeutic Targets for Bone and Soft-Tissue Sarcomas. Int. J. Mol. Sci. 2019, 20, 170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zahm, S.H.; Heineman, E.F.; Vaught, J.B. Soft tissue sarcoma and tobacco use: Data from a prospective cohort study of United States veterans. Cancer Causes Control 1992, 3, 371–376. [Google Scholar] [CrossRef] [PubMed]
- Gannon, N.P.; King, D.M.; Bedi, M. Smoking is predictive of poorer distant metastasis-free and progression free-survival in soft tissue sarcoma patients treated with pre-operative radiotherapy or chemoradiotherapy. Clin. Sarcoma Res. 2018, 8, 7. [Google Scholar] [CrossRef] [Green Version]
- Diessner, B.J.; Weigel, B.J.; Murugan, P.; Zhang, L.; Poynter, J.N.; Spector, L.G. Racial and Ethnic Differences in Sarcoma Incidence Are Independent of Census-Tract Socioeconomic Status. Cancer Epidemiol. Biomark. Prev. 2020, 29, 2141–2148. [Google Scholar] [CrossRef]
- Hsieh, M.C.; Wu, X.C.; Andrews, P.A.; Chen, V.W. Racial and Ethnic Disparities in the Incidence and Trends of Soft Tissue Sarcoma Among Adolescents and Young Adults in the United States, 1995–2008. J. Adolesc. Young Adult Oncol. 2013, 2, 89–94. [Google Scholar] [CrossRef] [PubMed]
- Worch, J.; Matthay, K.K.; Neuhaus, J.; Goldsby, R.; DuBois, S.G. Ethnic and racial differences in patients with Ewing sarcoma. Cancer 2010, 116, 983–988. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martinez, S.R.; Robbins, A.S.; Meyers, F.J.; Bold, R.J.; Khatri, V.P.; Goodnight, J.E., Jr. Racial and ethnic differences in treatment and survival among adults with primary extremity soft-tissue sarcoma. Cancer 2008, 112, 1162–1168. [Google Scholar] [CrossRef]
- Alamanda, V.K.; Song, Y.; Schwartz, H.S.; Holt, G.E. Racial Disparities in Extremity Soft-Tissue Sarcoma Outcomes: A Nationwide Analysis. Am. J. Clin. Oncol. 2015, 38, 595–599. [Google Scholar] [CrossRef]
- Patel, S.J.; Pappoppula, L.; Guddati, A.K. Analysis of Trends in Race and Gender Disparities in Incidence-Based Mortality in Patients Diagnosed with Soft Tissue Sarcomas from 2000 to 2016. Int. J. Gen. Med. 2021, 14, 3787–3791. [Google Scholar] [CrossRef] [PubMed]
- Lazarides, A.L.; Visgauss, J.D.; Nussbaum, D.P.; Green, C.L.; Blazer, D.G., 3rd; Brigman, B.E.; Eward, W.C. Race is an independent predictor of survival in patients with soft tissue sarcoma of the extremities. BMC Cancer 2018, 18, 488. [Google Scholar] [CrossRef] [PubMed]
Characteristic | N | Unadjusted HR (95% CI) |
---|---|---|
Sex | ||
Male | 1297 (50.5%) | 1.00 (referent) |
Female | 1273 (49.5%) | 0.91 (0.82–1.02) |
Age at Diagnosis (yrs) | ||
15–39 | 622 (24.2%) | 1.00 (referent) |
≥40 | 1948 (75.8%) | 1.28 *** (1.13–1.46) |
Ethnicity | ||
Non-Hispanic | 2296 (89.3%) | 1.00 (referent) |
Hispanic | 256 (10%) | 0.92 (0.76–1.12) |
Unknown | 18 (0.7%) | 1.65 (0.88–3.07) |
Race | ||
White | 2229 (86.7%) | 1.00 (referent) |
Black | 234 (9.1%) | 1.18 (0.98–1.42) |
Asian | 33 (1.3%) | 0.76 (0.41–1.43) |
Other | 62 (2.4%) | 1.06 (0.71–1.58) |
Unknown | 12 (0.5%) | 1.47 (0.70–3.09) |
Tobacco Use | ||
Never | 1320 (51.4%) | 1.00 (referent) |
Former User | 711 (27.7%) | 1.10 (0.96–1.25) |
Current User | 398 (15.5%) | 1.24 ** (1.06–1.44) |
Unknown | 141 (5.5%) | 1.07 (0.85–1.35) |
Sarcoma type | ||
Bone Sarcoma | 533 (20.7%) | 1.00 (referent) |
STS | 2037 (79.3%) | 1.11 (0.97–1.27) |
Spread | ||
Localized | 1873 (72.9%) | 1.00 (referent) |
Metastatic | 672 (26.1%) | 2.45 **** (2.19–2.74) |
Undefined | 10 (0.4%) | 1.24 (0.56–2.78) |
Unknown | 15 (0.6%) | 1.16 (0.60–2.24) |
First Treatment | ||
None | 88 (3.4%) | 1.00 (referent) |
Chemotherapy | 191 (7.4%) | 1.21 (0.87–1.69) |
Radiation Therapy | 40 (1.6%) | 2.20 *** (1.40–3.47) |
Surgery | 908 (35.3%) | 0.39 **** (0.29–0.52) |
Multiple Treatments | 1343 (52.3%) | 0.52 **** (0.39–0.70) |
First Treatment Included Chemotherapy | ||
Yes | 1047 (40.7%) | 1.00 (referent) |
No | 1523 (59.3%) | 0.62 **** (0.56–0.70) |
First Treatment Included Surgery | ||
Yes | 2167 (84.3%) | 1.00 (referent) |
No | 403 (15.7%) | 2.73 **** (2.39–3.13) |
First Treatment Included Radiation | ||
Yes | 835 (32.5%) | 1.00 (referent) |
No | 1735 (67.5%) | 1.06 (0.94–1.19) |
Family history | ||
No | 1284 (50%) | 1.00 (referent) |
Yes, one member only | 639 (24.9%) | 1.03 (0.90–1.17) |
Yes, multiple members | 647 (25.2%) | 0.99 (0.86–1.13) |
Overall Survival aHR (95% CI) a | |
---|---|
Age at Diagnosis (yrs) | |
15–39 | 1.00 (referent) |
≥40 | 1.54 **** (1.34–1.78) |
Ethnicity | |
Non-Hispanic | 1.00 (referent) |
Hispanic | 1.01 (0.83–1.23) |
Unknown | 2.00 * (1.07–3.74) |
Tobacco Use | |
Never | 1.00 (referent) |
Former User | 1.07 (0.93–1.22) |
Current User | 1.18 * (1.01–1.37) |
Unknown | 1.00 (0.79–1.26) |
Sarcoma Type | |
Bone sarcoma | 1.00 (referent) |
STS | 1.07 (0.92–1.23) |
Spread | |
Localized | 1.00 (referent) |
Metastatic | 2.19 **** (1.95–2.47) |
Undefined | 1.10 (0.49–2.46) |
Unknown | 1.12 (0.58–2.16) |
First Course of Treatment Included Chemotherapy | |
Yes | 1.00 (referent) |
No | 0.77 **** (0.69–0.87) |
First Course of Treatment Included Surgery | |
Yes | 1.00 (referent) |
No | 2.11 **** (1.82–2.45) |
First Course of Treatment Included Radiation | |
Yes | 1.00 (referent) |
No | 0.97 (0.86–1.09) |
1986–1994 aHR a (95% CI) | 1995–1999 aHR a (95% CI) | 2000–2005 aHR a (95% CI) | 2006–2010 aHR a (95% CI) | 2011–2014 aHR a (95% CI) | |
---|---|---|---|---|---|
N = 207 | N = 208 | N = 636 | N = 795 | N = 724 | |
Age at Diagnosis (yrs) | |||||
15–39 | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
≥40 | 2.03 *** (1.37–3.03) | 1.72 * (1.10–2.71) | 1.29 * (1.02–1.64) | 1.35 * (1.03–1.78) | 2.21 *** (1.38–3.53) |
Tobacco use | |||||
Never | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Former user | 0.80 (0.52–1.24) | 1.25 (0.81–1.93) | 1.21 (0.96–1.53) | 0.97 (0.76–1.22) | 1.36 (0.96–1.92) |
Current user | 0.84 (0.57–1.25) | 1.02 (0.62–1.68) | 1.39 * (1.06–1.83) | 1.05 (0.79–1.39) | 1.51 (0.96–2.37) |
Unknown | 0.72 (0.42–1.23) | 0.75 (0.43–1.32) | 1.40 (0.92–2.14) | 2.19 * (1.02–4.71) | 0.96 (0.54–1.72) |
Sarcoma type | |||||
Bone sarcoma | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
STS | 1.31 (0.88–1.94) | 1.69 * (1.11–2.58) | 1.19 (0.91–1.56) | 0.81 (0.62–1.05) | 0.73 (0.47–1.14) |
Spread | |||||
Localized | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
Metastatic | 2.20 **** (1.58–3.06) | 2.48 **** (1.71–3.60) | 2.14 **** (1.73–2.64) | 2.26 **** (1.82–2.79) | 1.86 *** (1.31–2.63) |
Undefined | NE | NE | 1.52 (0.45–5.10) | 0.97 (0.13–6.97) | 2.45 (0.59–10.19) |
Unknown | 0.62 (0.08–4.66) | 1.51 (0.54–4.25) | 0.49 (0.07–3.56) | NE | 1.96 (0.59–6.53) |
First Course of Treatment Included Chemotherapy | |||||
Yes | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
No | 1.03 (0.72–1.46) | 0.74 (0.51–1.09) | 0.72 ** (0.59–0.89) | 0.66 *** (0.53–0.83) | 0.69 * (0.49–0.97) |
First Course of Treatment Included Surgery | |||||
Yes | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) | 1.00 (referent) |
No | 1.68 * (1.10–2.55) | 4.91 **** (3.01–8.01) | 2.54 **** (1.95–3.31) | 1.72 *** (1.30–2.28) | 2.48 **** (1.71–3.59) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Stricker, E.; Reed, D.R.; Schabath, M.B.; Sok, P.; Scheurer, M.E.; Lupo, P.J. Trends in Overall Survival among Patients Treated for Sarcoma at a Large Tertiary Cancer Center between 1986 and 2014. Cancers 2023, 15, 514. https://doi.org/10.3390/cancers15020514
Stricker E, Reed DR, Schabath MB, Sok P, Scheurer ME, Lupo PJ. Trends in Overall Survival among Patients Treated for Sarcoma at a Large Tertiary Cancer Center between 1986 and 2014. Cancers. 2023; 15(2):514. https://doi.org/10.3390/cancers15020514
Chicago/Turabian StyleStricker, Erik, Damon R. Reed, Matthew B. Schabath, Pagna Sok, Michael E. Scheurer, and Philip J. Lupo. 2023. "Trends in Overall Survival among Patients Treated for Sarcoma at a Large Tertiary Cancer Center between 1986 and 2014" Cancers 15, no. 2: 514. https://doi.org/10.3390/cancers15020514
APA StyleStricker, E., Reed, D. R., Schabath, M. B., Sok, P., Scheurer, M. E., & Lupo, P. J. (2023). Trends in Overall Survival among Patients Treated for Sarcoma at a Large Tertiary Cancer Center between 1986 and 2014. Cancers, 15(2), 514. https://doi.org/10.3390/cancers15020514